Mk-677 Vs Ipamorelin
MK-677 vs Ipamorelin
The short answer
MK-677 (ibutamoren) is an orally active ghrelin mimetic taken daily, while ipamorelin is an injectable, selective growth hormone secretagogue (Nass et al., 2008; Raun et al., 1998).
This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.
What is the core difference between MK-677 and ipamorelin?
MK-677 is an oral, long-acting ghrelin receptor agonist, and ipamorelin is an injectable, short-acting selective GH secretagogue. Both push the body to release its own growth hormone, but they do it through different pharmacology and on very different schedules. MK-677 (ibutamoren) mimics ghrelin at the receptor and stays active long enough for once-daily oral use, which is why the 2-year trial by Nass et al. (2008) dosed it that way. Ipamorelin is a small peptide studied by injection, and the early work by Raun et al. (1998) framed its selling point as selectivity: it triggered GH release without the cortisol and prolactin spikes seen with some other secretagogues.
How are MK-677 and ipamorelin taken, and how long do they last?
MK-677 is oral and long-acting; ipamorelin is subcutaneous and short-acting. This is the first fork in any comparison. In the Nass et al. (2008) trial, participants took MK-677 by mouth once daily across a 2-year trial, which reflects its extended activity. Ipamorelin, by contrast, was characterized as a peptide GH secretagogue given by injection in the foundational research (Raun et al., 1998). Peptide secretagogues of this class generally act over a short window, which is part of why they are dosed by injection rather than a single daily pill.
| Feature | MK-677 (ibutamoren) | Ipamorelin |
|---|---|---|
| Class | Oral ghrelin mimetic | Selective GH secretagogue peptide |
| Route studied | Oral, once daily (Nass et al., 2008) | Subcutaneous injection (Raun et al., 1998) |
| Duration of action | Long-acting, supports daily oral use | Short-acting |
| Selectivity note | Ghrelin receptor agonist | Minimal cortisol/prolactin effect reported (Raun et al., 1998) |
| Key metabolic caution | Raised fasting glucose, lower insulin sensitivity (Nass et al., 2008) | Limited human trial data |
What does research report for MK-677 dosing and effects?
In the trial by Nass et al. (2008), participants received 25 mg/day of oral MK-677 across a 2-year trial, and researchers reported about 1.1 kg of fat-free mass at the 12-month mark of gained fat-free mass. That same study also reported raised fasting glucose and reduced insulin sensitivity, which is the metabolic flag researchers attach to this compound. These figures describe what one published trial reported in older adults; they are not a dose recommendation. Any personal dosing question belongs with a qualified clinician who can weigh the glucose signal against a specific health picture.
| Compound | Research-reported dose | Duration | Reported outcome | Citation |
|---|---|---|---|---|
| MK-677 | 25 mg/day, oral | 2-year trial (12-month readout) | +1.1 kg fat-free mass; raised fasting glucose; lower insulin sensitivity | Nass et al., 2008 |
| Ipamorelin | Not established in a comparable human trial | Not applicable | Selective GH release, minimal cortisol/prolactin (preclinical) | Raun et al., 1998 |
What does research report for ipamorelin?
Ipamorelin was described in early endocrinology research as a selective GH secretagogue that released growth hormone without meaningfully raising cortisol or prolactin (Raun et al., 1998). That selectivity is the reason it draws interest as a cleaner hormone signal. The honest limit here is data depth: ipamorelin does not have a long-term human outcome trial on the scale of the Nass et al. (2008) MK-677 study. So while the mechanism is well described, human efficacy and safety over months of use are not well documented in completed trials, and that gap should shape expectations.
Which one has the bigger metabolic caution?
MK-677 carries the clearer metabolic flag, because the 2-year trial reported raised fasting glucose and lower insulin sensitivity at 25 mg/day (Nass et al., 2008). That matters most for anyone with glucose concerns, because a compound that nudges fasting glucose upward over months is a real consideration, not a footnote. Ipamorelin's reported profile was cleaner on cortisol and prolactin (Raun et al., 1998), but the absence of long human trials means its long-term metabolic behavior is simply less documented. Neither point tells you what to take. Both point to the same step: a clinician review before any use.
How do their side-effect profiles compare?
MK-677's documented concern is metabolic (glucose and insulin sensitivity), while ipamorelin's reported advantage is hormonal selectivity. The Nass et al. (2008) data ties MK-677 to a measurable glucose signal over 12 months. Ipamorelin's preclinical description emphasized that it did not meaningfully raise cortisol or prolactin (Raun et al., 1998), which is the opposite kind of concern: hormone spillover rather than glucose. For research context, other secretagogues in this broad space have their own signals; for example, sustained GH/IGF-1 elevation has been shown with CJC-1295 (Teichman et al., 2006), which is why selectivity and duration are studied so closely across this class.
Keep reading
Related research and verification
Mk-677 Vs Ipamorelin: FAQ
Sourcing research-grade peptides?
Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.
References
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized, controlled trial. Annals of Internal Medicine. 2008;149(9):601-611 (PMID 18981485). Two-year randomized trial (body composition reported at the 12-month mark) where older adults taking MK-677 at 25 mg per day gained about 1.1 kg of fat-free mass but showed raised fasting glucose and lower insulin sensitivity.
- Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. doi:10.1530/eje.0.1390552 (PMID 9849822). Preclinical characterization of ipamorelin as a selective GH releaser with minimal effect on cortisol and prolactin.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536 (PMID 16352683). Cited for research context that sustained GH and IGF-1 elevation has been shown with CJC-1295.
General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.